CYP3A phenotypes and genotypes in North Indians

European Journal of Clinical Pharmacology

Volumn 62, Issue 6, 2006, Pages 417-422

  Rais, Naushad ^a   Chawla, Yogesh K ^a   Kohli, Krishan K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Cytochrome P450 3A; Genetic polymorphism; Pharmacogenetics; Pharmacogenomics

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; CYTOCHROME P450 3A; HYDROCORTISONE;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENOTYPE; HETEROZYGOTE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE URINE LEVEL; INDIAN; MALE; NORMAL HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; URINALYSIS;

ADULT; ALLELES; BASE SEQUENCE; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYDROCORTISONE; INDIA; MALE; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 33745027669     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-006-0105-3     Document Type: Article

References (40)

1. Tateishi T, Watanabe M, Moriya H, Yamaguchi S, Sato T, Kobayashi S (1999) No ethnic difference between Caucasians and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 57:935-939
2. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391
3. Watkins PB (1994) Noninvasive tests of CYP3A enzymes. Pharmacogenetics 4:171-184
4. Zaigler M, Tantcheva-Poor I, Fuhr U (2000) Problems and perspectives of phenotyping for drug metabolizing enzymes in man. Int J Clin Pharmacol Ther 38:1-9
5. Westlind A, Lofberg L, Tindberg N, Andersson TB, Ingelman-Sundberg M (1999) Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′- upstream regulatory region. Biochem Biophys Res Comm 259:201-205
6. Zhu B, Liu Z-Q, Chen G-L, Chen X-P, Ou-Yang D-S, Wang L-S, Huang S-L, Tan Z-R, Zhou H-H (2003) The distribution and gender difference of CYP3A activity in Chinese subjects. Br J Clin Pharmacol 55:264-269
7. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, Kamataki T (1993) Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur J Biochem 218:585-595
8. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90:1225-1229
9. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinryb I, Guida M, Hopkins PJ, Warner N, Hall J (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66:288-294
10. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ (2000) CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56
11. Hsieh K-P, Lin Y-Y, Cheng C-L, Lai M-L, Lin M-S, Siest J-P, Huang J-D (2001) Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 29:268-273
12. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedal E, Hustert E, Zanger UM, Brockmoller J, Klenk H-P, Meyer UA, Khan KK, He Y-A, Halpert JR, Wojnowski L (2001) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458
13. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-132
14. Dai D, Tang J, Rose R, Hodgson E, Bienstock RJ, Mohrenweiser HW, Goldstein JA (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exper Ther 299:825-831
15. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJD (2003) Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 13:89-95
16. Lamba JK, Dhiman RK, Kohli KK (2000) CYP2C19 genetic mutations in North Indians. Clin Pharmacol Ther 68:328-335
17. Adithan C, Gerard N, Vasu S, Rosemary J, Shashindran CH, Krishnamoorthy R (2003) Allele and genotype frequency of CYP2C19 in a Tamilian population. Br J Clin Pharmacol 56:331-333
18. Lykkesfeldt J, Loft S, Poulsen HE (1994) Simultaneous determination of urinary free cortisol and 6β-hydroxycortisol by high-performance liquid chromatography to measure human CYP3A activity. J Chromatogr B 660:23-29
19. Daly AK, Steen VM, Fairbrother KS, Idle JR (1996) CYP2D6 multiallelism. Methods Enzymol 272:199-210
20. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P (1989) The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 28:373-387
21. Ozdemir V, Kalow W, Tang B-K, Paterson AD, Walker SE, Endrenyi L, Kashuba ADM (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10:373-388
22. Kleinbloesem CH, van Brummelen P, Faber H, Danhof M, Vermeulen NPE, Breimer DD (1984) Variability in nifedipine pharmacokinetics and dynamics: A new oxidation polymorphism in man. Biochem Pharmacol 33:3721-3724
23. Schellens JHM, Soons PA, Breimer DD (1988) Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects. Biochem Pharmacol 37:2507-2510
24. Horsmans Y, Desager JP, Harvengt C (1992) Absence of CYP3A genetic polymorphism assesed by urinary excretion of 6β-hydroxycortisol in 102 healthy subjects on rifampicin. Pharmacol Toxicol 71:258-261
25. Inagaki K, Inagaki M, Kataoka T, Sekido I, Gill MA, Nishida M (2002) A wide interindividual variability of urinary 6β-hydroxycortisol to free cortisol in 487 healthy Japanese subjects in near basal condition. Ther Drug Monitor 24:722-727
26. Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, Kobayashi S, Thummel KE, Wilkinson GR (2001) CYP3A activity in European American and Japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther 69:333-339
27. Yu K-S, Cho J-Y, Shon J-H, Bae K-S, Yi S-Y, Lim H-S, Jang I-J, Shin S-G (2001) Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin Pharmacol Ther 70:228-236
28. Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD (1996) Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 50:52-59
29. Hunt CM, Westerkam WR, Stave GM (1992) Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44:275-283
30. Watkins PB, Turgeon DK, Saenger P, Lown KS, Kolars JC, Hamilton T, Fishman K, Guzelian PS, Voorhees JJ (1992) Comparison of urinary 6-β-cortisol and the erythromycin breath test as measures of hepatic P450IIIA (CYP3A) activity. Clin Pharmacol Ther 52:265-273
31. Ng MCY, Young RP, Critchley JAJH, Leung NWY, Lau JWY, Li AKC (1996) Urinary 6β-hydroxycortisol excretion in Hong Kong Chinese patients with hepatocellular carcinoma and other chronic liver diseases. Cancer 77:1427-1433
32. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD (2003) The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74:275-287
33. Wang A, Yu B-N, Luo C-H, Tan Z-R, Zhou G, Wang L-S, Zhang W, Li Z, Liu J, Zhou H-H (2005) Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients. Eur J Clin Pharmacol 60:843-848
34. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M (2003) Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761
35. Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, Klein K, Fromm MF, Nuessler AK, Neuhaus P, Zanger UM, Eichelbaum M, Wojnowski L (2002) Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem 277:24280-24288
36. Rodriguez-Antona C, Jande M, Rane A, Ingelman-Sundberg M (2005) Identification and phenotype characterization of two CYP3A haplotypes causing different enzymatic capacity in fetal liver. Clin Pharmacol Ther 77:259-270
37. Goodwin B, Hodgson E, Liddle C (1999) The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol Pharmacol 56:1329-1339
38. Goodwin B, Hodgson E, D'Costa DJ, Robertson GR, Liddle C (2002) Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol Pharmacol 62:359-365
39. Lim YP, Liu CH, Shyu LJ, Huang JD (2005) Functional characterization of a novel polymorphism of pregnane X receptor, Q158K, in Chinese subjects. Pharmacogenet Genomics 15:337-341
40. Cavalli SA, Hirata MH, Hirata RDC (2001) Detection of Mbo II polymorphism at the 5′ promoter region of CYP3A4. Clin Chem 47:348-351